Phreesia (NYSE:PHR) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Phreesia from “Buy” to “Hold,” contributing to an overall MarketBeat analyst consensus of “Hold” with an average price target of $15.25.
• Phreesia reported quarterly revenue of $129.46 million, slightly above estimates and up 10.4% year over year, but earnings per share of $0.03 fell short of the $0.09 consensus.
• Shares opened at $10.97, well below their 52-week high of $30.43, while institutional investors own approximately 92.1% of the company.

Phreesia (NYSE:PHR - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued on Saturday, Wall Street Zen reports.

PHR has been the topic of several other research reports. Barclays reaffirmed an "equal weight" rating and set a $10.00 price objective (down from $24.00) on shares of Phreesia in a research note on Thursday, May 14th. Weiss Ratings raised Phreesia from a "sell (d)" rating to a "sell (d+)" rating in a research note on Monday, July 20th. Needham & Company LLC restated a "buy" rating and issued a $14.00 price target on shares of Phreesia in a report on Monday, August 31st. Canaccord Genuity Group reiterated a "buy" rating and set a $16.00 price objective on shares of Phreesia in a report on Thursday. Finally, Truist Financial boosted their price objective on Phreesia from $11.00 to $12.00 and gave the company a "hold" rating in a research report on Thursday, May 28th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $15.25.

Phreesia Stock Down 1.2%

Shares of NYSE:PHR opened at $10.97 on Friday. The company has a 50 day moving average price of $11.25 and a two-hundred day moving average price of $10.47. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.76 and a current ratio of 1.76. The company has a market capitalization of $678.06 million, a PE ratio of 64.53 and a beta of 0.86. Phreesia has a 52 week low of $7.77 and a 52 week high of $30.43.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings results on Wednesday, September 2nd. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by ($0.06). Phreesia had a return on equity of 5.35% and a net margin of 2.06%.The firm had revenue of $129.46 million for the quarter, compared to the consensus estimate of $129.06 million. During the same period in the prior year, the business earned $0.01 earnings per share. The company's revenue for the quarter was up 10.4% compared to the same quarter last year. Analysts forecast that Phreesia will post 0.39 earnings per share for the current year.

Institutional Trading of Phreesia

A number of institutional investors have recently modified their holdings of PHR. Van ECK Associates Corp raised its position in Phreesia by 78.7% in the 4th quarter. Van ECK Associates Corp now owns 2,502 shares of the company's stock valued at $42,000 after buying an additional 1,102 shares during the last quarter. Rockefeller Capital Management L.P. boosted its position in Phreesia by 354.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company's stock worth $47,000 after acquiring an additional 2,149 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Phreesia by 1,119.8% during the 1st quarter. EverSource Wealth Advisors LLC now owns 3,269 shares of the company's stock worth $27,000 after acquiring an additional 3,001 shares during the last quarter. New York State Teachers Retirement System bought a new position in shares of Phreesia during the 1st quarter worth approximately $44,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of Phreesia by 332.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,610 shares of the company's stock worth $160,000 after acquiring an additional 4,313 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors.

Key Headlines Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: RBC Capital reiterated a Buy rating on Phreesia, supporting the investment case despite recent earnings pressure. Phreesia Receives a Buy from RBC Capital
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and assigned a $19 price target, while Canaccord Genuity reaffirmed its Buy rating with a $16 target. The targets imply substantial upside from the recent trading level and indicate analysts remain confident in Phreesia’s longer-term prospects.
• Positive Sentiment: Second-quarter fiscal 2027 revenue increased approximately 10% year over year to $129.5 million, slightly exceeding consensus expectations. Adjusted EBITDA reached $32.9 million, highlighting continued operating profitability and scale. Phreesia Q2 Fiscal 2027 Revenue Rises 10 Percent
• Neutral Sentiment: Analyst commentary remains constructive, but the wide gap between current trading levels and price targets suggests the market is waiting for clearer evidence that Phreesia can accelerate earnings growth.
• Negative Sentiment: Phreesia reported quarterly EPS of $0.03, below the consensus estimate of $0.09. The earnings shortfall overshadowed the revenue beat and likely drove the negative investor reaction. Phreesia Shares Sink After 2Q Earnings Underwhelm

About Phreesia

Phreesia, Inc NYSE: PHR is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.